- The FcResolv™ hIL-15 NOG is a super immunodeficient NOG mouse that expresses human IL-15 to support engraftment of human NK cells and which has a further reduction in residual murine immune activity via ablation of mouse Fc gamma receptors (FcγRs) in order to reduce experimental confounders.
- Murine FcγRs can confound experiments in several ways, leading to false positive or negative results. Removing murine FcγRs provides improved accuracy for efficacy assessment of antibody-based therapies which include an Fc domain.
- Lacks all murine FcγRs, including the FcγRI, IIB, III and IV types, along with the high affinity FcεRI receptor. The low affinity FcεRII receptor remains present.
- Supports engraftment of human NK cells following engraftment with CD56+ NK cells derived from PBMCs and can be used in a similar fashion to the hIL-15 NOG.
- The FcResolv hIL-15 NOG mouse is optimized for engraftment of isolated primary human NK cells, immortalized human NK cell lines or human NK cell therapies. Humanization with HSCs is not recommended in this model. While HSC engraftment results in strong proliferation of NK cells, lifespan post-differentiation is very limited. Humanization of this strain with PBMCs is not recommended as an optimal model to study human NK cells, but may be of interest for GvHD applications.
- Useful for efficacy studies involving antibody therapeutics with antibody-dependent cell cytotoxicity (ADCC) mechanism of action.
- Applications in research involving cancer, infectious disease, immunology, regenerative medicine, and human immune system engraftment.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.
Origin:
The FcResolv hIL-15 NOG mouse was developed by Takeshi Takahashi of the Central Institute for Experimental Animals (CIEA) in Japan. The Fcer1gtm1Rav mutation was developed in the laboratory of J.V. Ravetch, Sloan-Kettering Institute. The Fcgr2btm1Ttk mutation was developed in the laboratory of T. Takai of Okayama University. These two mutations were backcrossed onto the CIEA NOG mouse®, and the resulting FcResolv NOG mouse was crossed to the hIL-15 NOG to generate the FcResolv hIL-15 NOG. Taconic received stock in 2021, and the line was derived through embryo transfer. The mice are maintained by breeding females homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid and Il2rgtm1Sug mutant alleles with males that are homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid alleles and hemizygous for the Il2rgtm1Sug mutant allele and hIL-15 transgene or females homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid and Il2rgtm1Sug mutant alleles and hemizygous for the hIL-15 transgene by males homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid alleles and hemizygous for the Il2rgtm1Sug mutant allele.
Availability:
Available now*
*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3-weeks of age. Color:
Albino Species:
Mouse Initial Publication:
Katano I, Ito R, Kawai K, Takahashi T. Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse. Front Immunol. 2020 Oct 7;11:532684.